H
Huib N. Caron
Researcher at University of Amsterdam
Publications - 74
Citations - 10178
Huib N. Caron is an academic researcher from University of Amsterdam. The author has contributed to research in topics: Neuroblastoma & Gene. The author has an hindex of 41, co-authored 72 publications receiving 9388 citations. Previous affiliations of Huib N. Caron include Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
N-myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis.
Kathy Boon,Kathy Boon,Huib N. Caron,Ronald van Asperen,Linda J. Valentijn,Marie Christine Hermus,Peter van Sluis,Ilja Roobeek,Isabel Weis,P.A. Voûte,Manfred Schwab,Rogier Versteeg +11 more
TL;DR: In this paper, the authors applied serial analysis of gene expression (SAGE) to identify targets of N-myc in neuroblastoma cells and found that the large majority of the ribosomal proteins were induced, as well as genes controlling rRNA maturation.
Journal ArticleDOI
Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations
Thomas F. Eleveld,Derek A. Oldridge,Virginie Bernard,Jan Koster,Leo Colmet Daage,Sharon J. Diskin,Linda Schild,Nadia Bessoltane Bentahar,Angela Bellini,Mathieu Chicard,Eve Lapouble,Valérie Combaret,Patricia Legoix-Né,Jean Michon,Trevor J. Pugh,Lori S. Hart,JulieAnn Rader,Edward F. Attiyeh,Jun S. Wei,Shile Zhang,Arlene Naranjo,Julie M. Gastier-Foster,Michael D. Hogarty,Shahab Asgharzadeh,Malcolm A. Smith,Jaime M. Guidry Auvil,Thomas B.K. Watkins,Danny A. Zwijnenburg,Marli E. Ebus,Peter van Sluis,Anne Hakkert,Esther M. van Wezel,C. Ellen van der Schoot,Ellen M. Westerhout,Johannes H. Schulte,Godelieve A.M. Tytgat,M. Emmy M. Dolman,Isabelle Janoueix-Lerosey,Daniela S Gerhard,Huib N. Caron,Olivier Delattre,Javed Khan,Rogier Versteeg,Gudrun Schleiermacher,Jan J. Molenaar,John M. Maris +45 more
TL;DR: It is shown that RAS-MAPK pathway mutations may function as a biomarker for new therapeutic approaches to refractory disease and provide a rationale for genetic characterization of relapse neuroblastomas.
Journal ArticleDOI
Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study.
Elvira C. van Dalen,Helena J.H. van der Pal,Wouter E.M. Kok,Huib N. Caron,Leontien C. M. Kremer +4 more
TL;DR: One in every 10 children treated with a cumulative anthracycline dose of 300 mg/m2 or more will eventually develop A-CHF, a extremely high risk and it reinforces the need of re-evaluating the cumulative AnthracyCline dose used in different treatment protocols.
Journal ArticleDOI
NF1 Is a Tumor Suppressor in Neuroblastoma that Determines Retinoic Acid Response and Disease Outcome
Michael Hölzel,Sidong Huang,Jan Koster,Ingrid Øra,Arjan Lakeman,Huib N. Caron,Wouter Nijkamp,Jing Xie,Tom Callens,Shahab Asgharzadeh,Robert C. Seeger,Ludwine Messiaen,Rogier Versteeg,René Bernards +13 more
TL;DR: Using a large-scale RNAi genetic screen, crosstalk between the tumor suppressor NF1 and retinoic acid-induced differentiation in neuroblastoma is identified and inhibition of MEK signaling downstream of NF1 restores responsiveness to RA, suggesting a therapeutic strategy to overcome RA resistance in NF1-deficient neuroblastomas.
Journal ArticleDOI
Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma
TL;DR: LOH 1p was shown to be the most significant predictor of a poor outcome (P < 0.00001), independent of age and stage, and is also of prognostic value in those cases without N-myc amplification, indicating a stronger prognosticvalue for LOH 1 p.